Recurrence and rejection in liver transplantation for primary sclerosing cholangitis

World Journal of Gastroenterology

Volumn 18, Issue 1, 2012, Pages 1-15

  Fosby, Bjarte ^a,b   Karlsen, Tom H ^b   Melum, Espen ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Liver transplantation; Primary sclerosing cholangitis; Recurrence; Rejection

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ARTICLE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; PATHOGENESIS; PRIMARY SCLEROSING CHOLANGITIS; RISK FACTOR;

EID: 84855528731     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v18.i1.1     Document Type: Article

References (182)

1. Farrant JM, Hayllar KM, Wilkinson ML, Karani J, Portmann BC, Westaby D, Williams R. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991; 100: 1710-1717
2. Tischendorf JJ, Hecker H, Krüger M, Manns MP, Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. Am J Gastroenterol 2007; 102: 107-114
3. Miki C, Harrison JD, Gunson BK, Buckels JA, McMaster P, Mayer AD. Infammatory bowel disease in primary scleros-ing cholangitis: an analysis of patients undergoing liver transplantation. Br J Surg 1995; 82: 1114-1117
4. Shorbagi A, Bayraktar Y. Primary sclerosing cholangitis--what is the difference between east and west? World J Gas-troenterol 2008; 14: 3974-3981
5. Aadland E, Schrumpf E, Fausa O, Elgjo K, Heilo A, Aakhus T, Gjone E. Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol 1987; 22: 655-664
6. Broomé U, Olsson R, Lööf L, Bodemar G, Hultcrantz R, Danielsson A, Prytz H, Sandberg-Gertzén H, Wallerstedt S, Lindberg G. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 610-615
7. Karlsen TH, Schrumpf E, Boberg KM. Update on primary sclerosing cholangitis. Dig Liver Dis 2010; 42: 390-400
8. Weismüller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP. The challenges in primary sclerosing cholan-gitis--aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol 2008; 48 Suppl 1: S38-S57
9. Adam R, Hoti E. Liver transplantation: the current situation. Semin Liver Dis 2009; 29: 3-18
10. Graziadei IW, Wiesner RH, Marotta PJ, Porayko MK, Hay JE, Charlton MR, Poterucha JJ, Rosen CB, Gores GJ, LaRusso NF, Krom RA. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999; 30: 1121-1127
11. Goss JA, Shackleton CR, Farmer DG, Arnaout WS, Seu P, Markowitz JS, Martin P, Stribling RJ, Goldstein LI, Busuttil RW. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg 1997; 225: 472-481; discussion 481-483
12. Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, Neu-berger J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 2008; 21: 459-465
13. Alabraba E, Nightingale P, Gunson B, Hubscher S, Olliff S, Mirza D, Neuberger J. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver al-lografts. Liver Transpl 2009; 15: 330-340
14. Clesca P, Dirlando M, Park SI, García R, Ferraz E, Pinheiro-Machado PG, Kushnaroff L, Tedesco-Silva H, Medina-Pes-tana JO. Thymoglobulin and rate of infectious complications after transplantation. Transplant Proc 2007; 39: 463-464
15. Guimarães-Souza NK, Dalboni MA, Câmara NC, Medina-Pestana JO, Paheco-Silva A, Cendoroglo M. Infectious complications after deceased kidney donor transplantation. Transplant Proc 2010; 42: 1137-1141
16. Selzner N, Grant DR, Shalev I, Levy GA. The immunosup-pressive pipeline: meeting unmet needs in liver transplantation. Liver Transpl 2010; 16: 1359-1372
17. Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, Loftus EV, Yawn BP, Dickson ER, Melton LJ. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastro-enterology 2003; 125: 1364-1369
18. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998; 33: 99-103
19. Kingham JG, Kochar N, Gravenor MB. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 2004; 126: 1929-1930
20. Kochhar R, Goenka MK, Das K, Nagi B, Bhasin DK, Chawla YK, Vaiphei K, Singh K, Dilawari JB. Primary sclerosing cholangitis: an experience from India. J Gastroenterol Hepatol 1996; 11: 429-433
21. Ang TL, Fock KM, Ng TM, Teo EK, Chua TS, Tan JY. Clinical profle of primary sclerosing cholangitis in Singapore. J Gastroenterol Hepatol 2002; 17: 908-913
22. Escorsell A, Parés A, Rodés J, Solís-Herruzo JA, Miras M, de la Morena E. Epidemiology of primary sclerosing cholangi-tis in Spain. Spanish Association for the Study of the Liver. J Hepatol 1994; 21: 787-791
23. Bjøro K, Brandsaeter B, Foss A, Schrumpf E. Liver transplantation in primary sclerosing cholangitis. Semin Liver Dis 2006; 26: 69-79
24. Lerut J, Demetris AJ, Stieber AC, Marsh JW, Gordon RD, Esquivel CO, Iwatsuki S, Starzl TE. Intrahepatic bile duct strictures after human orthotopic liver transplantation. Recurrence of primary sclerosing cholangitis or unusual presentation of allograft rejection? Transpl Int 1988; 1: 127-130
25. Schreuder TC, Hübscher SG, Neuberger J. Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far? Transpl Int 2009; 22: 144-152
26. Duclos-Vallee JC, Sebagh M. Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation. Liver Transpl 2009; 15 Suppl 2: S25-S34
27. Li KK, Neuberger J. Recurrent nonviral liver disease following liver transplantation. Expert Rev Gastroenterol Hepatol 2009; 3: 257-268
28. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006; 12: 1813-1824
29. Harrison RF, Davies MH, Neuberger JM, Hubscher SG. Fibrous and obliterative cholangitis in liver allografts: evidence of recurrent primary sclerosing cholangitis? Hepatol-ogy 1994; 20: 356-361
30. Narumi S, Roberts JP, Emond JC, Lake J, Ascher NL. Liver transplantation for sclerosing cholangitis. Hepatology 1995; 22: 451-457
31. Saldeen K, Friman S, Olausson M, Olsson R. Follow-up after liver transplantation for primary sclerosing cholangitis: effects on survival, quality of life, and colitis. Scand J Gastro-enterol 1999; 34: 535-540
32. Vera A, Moledina S, Gunson B, Hubscher S, Mirza D, Olliff S, Neuberger J. Risk factors for recurrence of primary scleros-ing cholangitis of liver allograft. Lancet 2002; 360: 1943-1944
33. Schwartz SI, Dale WA. Primary sclerosing cholangitis; review and report of six cases. AMA Arch Surg 1958; 77: 439-451
34. Chapman RW, Arborgh BA, Rhodes JM, Summerfield JA, Dick R, Scheuer PJ, Sherlock S. Primary sclerosing cholan-gitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980; 21: 870-877
35. Bergquist A, Montgomery SM, Bahmanyar S, Olsson R, Danielsson A, Lindgren S, Prytz H, Hultcrantz R, Lööf LA, Sandberg-Gertzén H, Almer S, Askling J, Ehlin A, Ekbom A. Increased risk of primary sclerosing cholangitis and ulcer-ative colitis in frst-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2008; 6: 939-943
36. Karlsen TH, Franke A, Melum E, Kaser A, Hov JR, Balschun T, Lie BA, Bergquist A, Schramm C, Weismüller TJ, Got-thardt D, Rust C, Philipp EE, Fritz T, Henckaerts L, Weers-ma RK, Stokkers P, Ponsioen CY, Wijmenga C, Sterneck M, Nothnagel M, Hampe J, Teufel A, Runz H, Rosenstiel P, Stiehl A, Vermeire S, Beuers U, Manns MP, Schrumpf E, Boberg KM, Schreiber S. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010; 138: 1102-1111
37. Melum E, Franke A, Schramm C, Weismüller TJ, Gotthardt DN, Offner FA, Juran BD, Laerdahl JK, Labi V, Björnsson E, Weersma RK, Henckaerts L, Teufel A, Rust C, Ellinghaus E, Balschun T, Boberg KM, Ellinghaus D, Bergquist A, Sauer P, Ryu E, Hov JR, Wedemeyer J, Lindkvist B, Wittig M, Porte RJ, Holm K, Gieger C, Wichmann HE, Stokkers P, Ponsioen CY, Runz H, Stiehl A, Wijmenga C, Sterneck M, Vermeire S, Beuers U, Villunger A, Schrumpf E, Lazaridis KN, Manns MP, Schreiber S, Karlsen TH. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet 2011; 43: 17-19
38. Schrumpf E, Fausa O, Førre O, Dobloug JH, Ritland S, Thorsby E. HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease. Scand J Gastroenterol 1982; 17: 187-191
39. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, Lee JC, Goyette P, Imielinski M, Latiano A, Lagacé C, Scott R, Amininejad L, Bumpstead S, Baidoo L, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Colombel JF, Denson LA, De Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann RS, Floyd JA, Florin T, Franchimont D, Franke L, Georges M, Glas J, Glazer NL, Guthery SL, Haritunians T, Hayward NK, Hugot JP, Jobin G, Laukens D, Lawrance I, Lémann M, Levine A, Libioulle C, Louis E, McGovern DP, Milla M, Montgomery GW, Mor-ley KI, Mowat C, Ng A, Newman W, Ophoff RA, Papi L, Palmieri O, Peyrin-Biroulet L, Panés J, Phillips A, Prescott NJ, Proctor DD, Roberts R, Russell R, Rutgeerts P, Sanderson J, Sans M, Schumm P, Seibold F, Sharma Y, Simms LA, Seielstad M, Steinhart AH, Targan SR, van den Berg LH, Vatn M, Verspaget H, Walters T, Wijmenga C, Wilson DC, Westra HJ, Xavier RJ, Zhao ZZ, Ponsioen CY, Andersen V, Torkvist L, Gazouli M, Anagnou NP, Karlsen TH, Kupcin-skas L, Sventoraityte J, Mansfeld JC, Kugathasan S, Silver-berg MS, Halfvarson J, Rotter JI, Mathew CG, Griffths AM, Gearry R, Ahmad T, Brant SR, Chamaillard M, Satsangi J, Cho JH, Schreiber S, Daly MJ, Barrett JC, Parkes M, Annese V, Hakonarson H, Radford-Smith G, Duerr RH, Vermeire S, Weersma RK, Rioux JD. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confrmed associations to 47. Nat Genet 2011; 43: 246-252
40. Franke A, Balschun T, Karlsen TH, Hedderich J, May S, Lu T, Schuldt D, Nikolaus S, Rosenstiel P, Krawczak M, Schreiber S. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcer-ative colitis. Nat Genet 2008; 40: 713-715
41. Saarinen S, Olerup O, Broomé U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol 2000; 95: 3195-3199
42. Hov JR, Boberg KM, Karlsen TH. Autoantibodies in primary sclerosing cholangitis. World J Gastroenterol 2008; 14: 3781-3791
43. Terjung B, Herzog V, Worman HJ, Gestmann I, Bauer C, Sauerbruch T, Spengler U. Atypical antineutrophil cyto-plasmic antibodies with perinuclear fuorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology 1998; 28: 332-340
44. Terjung B, Spengler U, Sauerbruch T, Worman HJ. "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000; 119: 310-322
45. Klein R, Eisenburg J, Weber P, Seibold F, Berg PA. Signif-cance and specifcity of antibodies to neutrophils detected by western blotting for the serological diagnosis of primary sclerosing cholangitis. Hepatology 1991; 14: 1147-1152
46. O'Mahony CA, Vierling JM. Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis 2006; 26: 3-21
47. Worthington J, Cullen S, Chapman R. Immunopathogenesis of primary sclerosing cholangitis. Clin Rev Allergy Immunol 2005; 28: 93-103
48. Lichtman SN, Okoruwa EE, Keku J, Schwab JH, Sartor RB. Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobili-ary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. J Clin Invest 1992; 90: 1313-1322
49. Lichtman SN, Keku J, Schwab JH, Sartor RB. Evidence for peptidoglycan absorption in rats with experimental small bowel bacterial overgrowth. Infect Immun 1991; 59: 555-562
50. Lichtman SN, Keku J, Schwab JH, Sartor RB. Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline. Gastroenterol-ogy 1991; 100: 513-519
51. Lichtman SN, Keku J, Clark RL, Schwab JH, Sartor RB. Biliary tract disease in rats with experimental small bowel bacterial overgrowth. Hepatology 1991; 13: 766-772
52. Lichtman SN, Sartor RB, Keku J, Schwab JH. Hepatic in-fammation in rats with experimental small intestinal bacterial overgrowth. Gastroenterology 1990; 98: 414-423
53. Boomkens SY, de Rave S, Pot RG, Egberink HF, Penning LC, Rothuizen J, Zondervan PE, Kusters JG. The role of He-licobacter spp. in the pathogenesis of primary biliary cirrhosis and primary sclerosing cholangitis. FEMS Immunol Med Microbiol 2005; 44: 221-225
54. Krasinskas AM, Yao Y, Randhawa P, Dore MP, Sepulveda AR. Helicobacter pylori may play a contributory role in the pathogenesis of primary sclerosing cholangitis. Dig Dis Sci 2007; 52: 2265-2270
55. Mehal WZ, Hattersley AT, Chapman RW, Fleming KA. A survey of cytomegalovirus (CMV) DNA in primary sclerosing cholangitis (PSC) liver tissues using a sensitive poly-merase chain reaction (PCR) based assay. J Hepatol 1992; 15: 396-399
56. Minuk GY, Rascanin N, Paul RW, Lee PW, Buchan K, Kelly JK. Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 1987; 5: 8-13
57. Kulaksiz H, Rudolph G, Kloeters-Plachky P, Sauer P, Geiss H, Stiehl A. Biliary candida infections in primary sclerosing cholangitis. J Hepatol 2006; 45: 711-716
58. Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of infammatory bowel disease. Nat Rev Immunol 2006; 6: 244-251
59. Salmi M, Jalkanen S. Endothelial ligands and homing of mucosal leukocytes in extraintestinal manifestations of IBD. Infamm Bowel Dis 1998; 4: 149-156
60. Grant AJ, Lalor PF, Hübscher SG, Briskin M, Adams DH. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology 2001; 33: 1065-1072
61. Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002; 359: 150-157
62. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F, Marschall HU, Tsybrovskyy O, Zatloukal K, Denk H, Trauner M. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002; 123: 1238-1251
63. Fickert P, Fuchsbichler A, Wagner M, Zollner G, Kaser A, Tilg H, Krause R, Lammert F, Langner C, Zatloukal K, Marschall HU, Denk H, Trauner M. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2004; 127: 261-274
64. Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D. Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fbrosis via massive dysregulation of pro- and antifbrogenic genes. J Hepatol 2005; 43: 1045-1054
65. Nakken KE, Nygård S, Haaland T, Berge KE, Arnkvaern K, Ødegaard A, Labori KJ, Raeder MG. Multiple infammato-ry-, tissue remodelling- and fbrosis genes are differentially transcribed in the livers of Abcb4 (-/-) mice harbouring chronic cholangitis. Scand J Gastroenterol 2007; 42: 1245-1255
66. Melum E, Boberg KM, Franke A, Bergquist A, Hampe J, Karlsen TH. Variation in the MDR3 gene infuences disease progression in PSC patients and disease susceptibility in epistatic interaction with a polymorphism in the OST-alpha gene. Hepatology 2007; 46: 265A
67. Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wage-naar E, van Deemter L, Mol CA, Ottenhoff R, van der Lugt NM, van Roon MA. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993; 75: 451-462
68. Trauner M, Fickert P, Wagner M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis 2007; 27: 77-98
69. Alexander J, Lord JD, Yeh MM, Cuevas C, Bakthavatsalam R, Kowdley KV. Risk factors for recurrence of primary scle-rosing cholangitis after liver transplantation. Liver Transpl 2008; 14: 245-251
70. Jeyarajah DR, Netto GJ, Lee SP, Testa G, Abbasoglu O, Husberg BS, Levy MF, Goldstein RM, Gonwa TA, Tillery GW, Crippin JS, Klintmalm GB. Recurrent primary scle-rosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process? Transplantation 1998; 66: 1300-1306
71. Khettry U, Keaveny A, Goldar-Najafi A, Lewis WD, Pomfret EA, Pomposelli JJ, Jenkins RL, Gordon FD. Liver transplantation for primary sclerosing cholangitis: a long-term clinicopathologic study. Hum Pathol 2003; 34: 1127-1136
72. Abu-Elmagd K, Demetris J, Rakela J, Kang Y, Martin D, Dvorchik I, McMicheal J, Balan V, Starzl T, Fung J. Recurrence of primary sclerosing cholangitis (PSC) after hepatic transplantation (HTx): single center experience with 380 grafts. Abstract of the 18th Annual Meeting of the American Society of Transplantation (AST), May 15-19, 1999. Transplantation 1999; 67: S236
73. Egawa H, Taira K, Teramukai S, Haga H, Ueda Y, Yone-zawa A, Masuda S, Tsuji H, Ashihara E, Takada Y, Uemoto S. Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation: a single center experience. Dig Dis Sci 2009; 54: 1347-1354
74. Haga H, Miyagawa-Hayashino A, Taira K, Morioka D, Ega-wa H, Takada Y, Manabe T, Uemoto S. Histological recurrence of autoimmune liver diseases after living-donor liver transplantation. Hepatol Res 2007; 37 Suppl 3: S463-S469
75. Brandsaeter B, Schrumpf E, Bentdal O, Brabrand K, Smith HJ, Abildgaard A, Clausen OP, Bjoro K. Recurrent primary sclerosing cholangitis after liver transplantation: a magnetic resonance cholangiography study with analyses of predictive factors. Liver Transpl 2005; 11: 1361-1369
76. Kugelmas M, Spiegelman P, Osgood MJ, Young DA, Trotter JF, Steinberg T, Wachs ME, Bak T, Kam I, Everson GT. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2003; 9: 727-732
77. Cholongitas E, Shusang V, Papatheodoridis GV, Marelli L, Manousou P, Rolando N, Patch D, Rolles K, Davidson B, Burroughs AK. Risk factors for recurrence of primary scle-rosing cholangitis after liver transplantation. Liver Transpl 2008; 14: 138-143
78. Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Steinberg T, Kam I. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl 2008; 14: 181-185
79. Sheng R, Zajko AB, Campbell WL, Abu-Elmagd K. Biliary strictures in hepatic transplants: prevalence and types in patients with primary sclerosing cholangitis vs those with other liver diseases. AJR Am J Roentgenol 1993; 161: 297-300
80. Campbell WL, Sheng R, Zajko AB, Abu-Elmagd K, Deme-tris AJ. Intrahepatic biliary strictures after liver transplantation. Radiology 1994; 191: 735-740
81. Letourneau JG, Day DL, Hunter DW, Ascher NL, Najarian JS, Thompson WM, Castaneda-Zuniga WR. Biliary complications after liver transplantation in patients with preexisting sclerosing cholangitis. Radiology 1988; 167: 349-351
82. Ward EM, Kiely MJ, Maus TP, Wiesner RH, Krom RA. Hilar biliary strictures after liver transplantation: cholangi-ography and percutaneous treatment. Radiology 1990; 177: 259-263
83. McDonald V, Matalon TA, Patel SK, Brunner MC, Sankary H, Foster P, Williams J. Biliary strictures in hepatic transplantation. J Vasc Interv Radiol 1991; 2: 533-538
84. McEntee G, Wiesner RH, Rosen C, Cooper J, Wahlstrom E. A comparative study of patients undergoing liver transplantation for primary sclerosing cholangitis and primary biliary cirrhosis. Transplant Proc 1991; 23: 1563-1564
85. Sheng R, Campbell WL, Zajko AB, Baron RL. Cholangio-graphic features of biliary strictures after liver transplantation for primary sclerosing cholangitis: evidence of recurrent disease. AJR Am J Roentgenol 1996; 166: 1109-1113
86. Graziadei IW. Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2002; 8: 575-581
87. Graziadei IW, Wiesner RH, Batts KP, Marotta PJ, LaRusso NF, Porayko MK, Hay JE, Gores GJ, Charlton MR, Ludwig J, Poterucha JJ, Steers JL, Krom RA. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepa-tology 1999; 29: 1050-1056
88. Abdalian R, Heathcote EJ. Sclerosing cholangitis: a focus on secondary causes. Hepatology 2006; 44: 1063-1074
89. Welsh FK, Wigmore SJ. Roux-en-Y Choledochojejunostomy is the method of choice for biliary reconstruction in liver transplantation for primary sclerosing cholangitis. Transplantation 2004; 77: 602-604
90. Akamatsu N, Sugawara Y, Hashimoto D. Biliary reconstruction, its complications and management of biliary complications after adult liver transplantation: a systematic review of the incidence, risk factors and outcome. Transpl Int 2011; 24: 379-392
91. Ostroff JW. Management of biliary complications in the liver transplant patient. Gastroenterol Hepatol (NY) 2010; 6: 264-272
92. Saleem A, Baron TH, Gostout CJ, Topazian MD, Levy MJ, Petersen BT, Wong Kee Song LM. Endoscopic retrograde cholangiopancreatography using a single-balloon entero-scope in patients with altered Roux-en-Y anatomy. Endos-copy 2010; 42: 656-660
93. Koornstra JJ. Double balloon enteroscopy for endoscopic retrograde cholangiopancreaticography after Roux-en-Y reconstruction: case series and review of the literature. Neth J Med 2008; 66: 275-279
94. Bennet W, Zimmerman MA, Campsen J, Mandell MS, Bak T, Wachs M, Kam I. Choledochoduodenostomy is a safe alternative to Roux-en-Y choledochojejunostomy for biliary reconstruction in liver transplantation. World J Surg 2009; 33: 1022-1025
95. Campsen J, Zimmerman MA, Mandell MS, Wachs M, Bak T, Forman L, Steinberg T, Kam I. Hepaticoduodenostomy is an alternative to Roux-en-Y hepaticojejunostomy for biliary reconstruction in live donor liver transplantation. Transplantation 2009; 87: 1842-1845
96. Weber C, Kuhlencordt R, Grotelueschen R, Wedegaertner U, Ang TL, Adam G, Soehendra N, Seitz U. Magnetic resonance cholangiopancreatography in the diagnosis of primary sclerosing cholangitis. Endoscopy 2008; 40: 739-745
97. Dave M, Elmunzer BJ, Dwamena BA, Higgins PD. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology 2010; 256: 387-396
98. Vitellas KM, El-Dieb A, Vaswani KK, Bennett WF, Tza-lonikou M, Mabee C, Kirkpatrick R, Bova JG. MR cholan-giopancreatography in patients with primary sclerosing cholangitis: interobserver variability and comparison with endoscopic retrograde cholangiopancreatography. AJR Am J Roentgenol 2002; 179: 399-407
99. Textor HJ, Flacke S, Pauleit D, Keller E, Neubrand M, Ter-jung B, Gieseke J, Scheurlen C, Sauerbruch T, Schild HH. Three-dimensional magnetic resonance cholangiopancrea-tography with respiratory triggering in the diagnosis of primary sclerosing cholangitis: comparison with endoscopic retrograde cholangiography. Endoscopy 2002; 34: 984-990
100. Dave M, Elmunzer BJ, Dwamena BA, Higgins PD. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology 2010; 256: 387-396
101. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-678
102. EASL Clinical Practice Guidelines: management of choles-tatic liver diseases. J Hepatol 2009; 51: 237-267
103. Angulo P, Pearce DH, Johnson CD, Henry JJ, LaRusso NF, Petersen BT, Lindor KD. Magnetic resonance cholangiogra-phy in patients with biliary disease: its role in primary scle-rosing cholangitis. J Hepatol 2000; 33: 520-527
104. Moff SL, Kamel IR, Eustace J, Lawler LP, Kantsevoy S, Kalloo AN, Thuluvath PJ. Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc 2006; 64: 219-223
105. Demetris AJ. Distinguishing between recurrent primary sclerosing cholangitis and chronic rejection. Liver Transpl 2006; 12: S68-S72
106. Adeyi O, Fischer SE, Guindi M. Liver allograft pathology: approach to interpretation of needle biopsies with clinico-pathological correlation. J Clin Pathol 2010; 63: 47-74
107. Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994; 20: 57-64
108. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursode-oxycholic acid in primary sclerosing cholangitis. Gastroen-terology 2001; 121: 900-907
109. Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, Weinzierl M, Pape GR, Sauerbruch T, Paumgartner G. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepa-tology 1992; 16: 707-714
110. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336: 691-695
111. Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hult-crantz R, Folvik G, Bell H, Gangsøy-Kristiansen M, Matre J, Rydning A, Wikman O, Danielsson A, Sandberg-Gertzén H, Ung KA, Eriksson A, Lööf L, Prytz H, Marschall HU, Broomé U. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129: 1464-1472
112. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, Mc-Cashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F. High-dose ursodeoxycholic acid for the treatment of primary scleros-ing cholangitis. Hepatology 2009; 50: 808-814
113. Shi J, Li Z, Zeng X, Lin Y, Xie WF. Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials. Hepatol Res 2009; 39: 865-873
114. Pardi DS, Loftus EV, Kremers WK, Keach J, Lindor KD. Ur-sodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 889-893
115. Stiehl A, Rudolph G, Klöters-Plachky P, Sauer P, Walker S. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxy-cholic acid: outcome after endoscopic treatment. J Hepatol 2002; 36: 151-156
116. Baluyut AR, Sherman S, Lehman GA, Hoen H, Chalasani N. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 2001; 53: 308-312
117. Gluck M, Cantone NR, Brandabur JJ, Patterson DJ, Bred-feldt JE, Kozarek RA. A twenty-year experience with endo-scopic therapy for symptomatic primary sclerosing cholan-gitis. J Clin Gastroenterol 2008; 42: 1032-1039
118. Maheshwari A, Yoo HY, Thuluvath PJ. Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. Am J Gastroenterol 2004; 99: 538-542
119. Marudanayagam R, Shanmugam V, Sandhu B, Gunson BK, Mirza DF, Mayer D, Buckels J, Bramhall SR. Liver retrans-plantation in adults: a single-centre, 25-year experience. HPB (Oxford) 2010; 12: 217-224
120. Reese PP, Yeh H, Thomasson AM, Shults J, Markmann JF. Transplant center volume and outcomes after liver retrans-plantation. Am J Transplant 2009; 9: 309-317
121. Akpinar E, Selvaggi G, Levi D, Moon J, Nishida S, Island E, DeFaria W, Pretto E, Ruiz P, Tzakis AG. Liver retransplanta-tion of more than two grafts for recurrent failure. Transplantation 2009; 88: 884-890
122. Postma R, Haagsma EB, Peeters PM, van den Berg AP, Slooff MJ. Retransplantation of the liver in adults: outcome and predictive factors for survival. Transpl Int 2004; 17: 234-240
123. Facciuto M, Heidt D, Guarrera J, Bodian CA, Miller CM, Emre S, Guy SR, Fishbein TM, Schwartz ME, Sheiner PA. Retransplantation for late liver graft failure: predictors of mortality. Liver Transpl 2000; 6: 174-179
124. Markmann JF, Markowitz JS, Yersiz H, Morrisey M, Farmer DG, Farmer DA, Goss J, Ghobrial R, McDiarmid SV, Strib-ling R, Martin P, Goldstein LI, Seu P, Shackleton C, Busuttil RW. Long-term survival after retransplantation of the liver. Ann Surg 1997; 226: 408-418; discussion 418-420
125. Neil DA, Hübscher SG. Current views on rejection pathology in liver transplantation. Transpl Int 2010; 23: 971-983
126. Uemura T, Ikegami T, Sanchez EQ, Jennings LW, Narasim-han G, McKenna GJ, Randall HB, Chinnakotla S, Levy MF, Goldstein RM, Klintmalm GB. Late acute rejection after liver transplantation impacts patient survival. Clin Transplant 2008; 22: 316-323
127. Neuberger J. Incidence, timing, and risk factors for acute and chronic rejection. Liver Transpl Surg 1999; 5: S30-S36
128. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658-663
129. Seiler CA, Dufour JF, Renner EL, Schilling M, Büchler MW, Bischoff P, Reichen J. Primary liver disease as a determinant for acute rejection after liver transplantation. Langenbecks Arch Surg 1999; 384: 259-263
130. Wiesner RH, Demetris AJ, Belle SH, Seaberg EC, Lake JR, Zetterman RK, Everhart J, Detre KM. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998; 28: 638-645
131. Farges O, Saliba F, Farhamant H, Samuel D, Bismuth A, Reynes M, Bismuth H. Incidence of rejection and infection after liver transplantation as a function of the primary disease: possible infuence of alcohol and polyclonal immuno-globulins. Hepatology 1996; 23: 240-248
132. Garcia RF, Garcia CE, McMaster P. Chronic rejection of the liver: the role of immunosuppression. BioDrugs 2000; 14: 283-297
133. Burra P, Senzolo M, Adam R, Delvart V, Karam V, Germani G, Neuberger J. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant 2010; 10: 138-148
134. Terminology for hepatic allograft rejection. International Working Party. Hepatology 1995; 22: 648-654
135. Knechtle SJ, Kwun J. Unique aspects of rejection and tolerance in liver transplantation. Semin Liver Dis 2009; 29: 91-101
136. Calne R. Immunological tolerance: the liver effect. J Gastro-enterol Hepatol 2002; 17 Suppl: S488-S490
137. Flye MW, Pennington L, Kirkman R, Weber B, Sindelar W, Sachs DH. Spontaneous acceptance or rejection of ortho-topic liver transplants in outbred and partially inbred miniature swine. Transplantation 1999; 68: 599-607
138. Kamada N, Calne RY. A surgical experience with fve hundred thirty liver transplants in the rat. Surgery 1983; 93: 64-69
139. Jahr H, Wolff H. The liver--an immunologically privileged organ?. Allerg Immunol (Leipz) 1989; 35: 155-166
140. Shaked A, Ghobrial RM, Merion RM, Shearon TH, Emond JC, Fair JH, Fisher RA, Kulik LM, Pruett TL, Terrault NA. Incidence and severity of acute cellular rejection in recipients undergoing adult living donor or deceased donor liver transplantation. Am J Transplant 2009; 9: 301-308
141. Tippner C, Nashan B, Hoshino K, Schmidt-Sandte E, Aki-maru K, Böker KH, Schlitt HJ. Clinical and subclinical acute rejection early after liver transplantation: contributing factors and relevance for the long-term course. Transplantation 2001; 72: 1122-1128
142. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet 1994; 344: 423-428
143. Howard TK, Klintmalm GB, Cofer JB, Husberg BS, Goldstein RM, Gonwa TA. The infuence of preservation injury on rejection in the hepatic transplant recipient. Transplantation 1990; 49: 103-107
144. Lan X, Zhang MM, Pu CL, Guo CB, Kang Q, Li YC, Dai XK, Deng YH, Xiong Q, Ren ZM. Impact of human leukocyte antigen mismatching on outcomes of liver transplantation: a meta-analysis. World J Gastroenterol 2010; 16: 3457-3464
145. Warlé MC, Metselaar HJ, Hop WC, Tilanus HW. Cytokine gene polymorphisms and acute liver graft rejection: a metaanalysis. Liver Transpl 2005; 11: 19-26
146. Adams D. Mechanisms of liver allograft rejection in man. Clin Sci (Lond) 1990; 78: 343-350
147. Jain A, Ryan C, Mohanka R, Orloff M, Abt P, Romano J, Bryan L, Batzold P, Mantry P, Bozorgzadeh A. Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in post-liver transplant biopsies. Clin Transplant 2006; 20: 624-633
148. Pratschke J, Stauch D, Kotsch K. Role of NK and NKT cells in solid organ transplantation. Transpl Int 2009; 22: 859-868
149. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005; 5: 201-214
150. Karlsen TH, Boberg KM, Olsson M, Sun JY, Senitzer D, Bergquist A, Schrumpf E, Thorsby E, Lie BA. Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis. J Hepatol 2007; 46: 899-906
151. Hov JR, Lleo A, Selmi C, Woldseth B, Fabris L, Strazzabosco M, Karlsen TH, Invernizzi P. Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defnes a critical role for HLA-C. J Hepatol 2010; 52: 712-717
152. Hashimoto E, Lindor KD, Homburger HA, Dickson ER, Czaja AJ, Wiesner RH, Ludwig J. Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis. Mayo Clin Proc 1993; 68: 1049-1055
153. Hata K, Van Thiel DH, Herberman RB, Whiteside TL. Phe-notypic and functional characteristics of lymphocytes isolated from liver biopsy specimens from patients with active liver disease. Hepatology 1992; 15: 816-823
154. Bishara A, Brautbar C, Zamir G, Eid A, Safadi R. Impact of HLA-C and Bw epitopes disparity on liver transplantation outcome. Hum Immunol 2005; 66: 1099-1105
155. Hanvesakul R, Spencer N, Cook M, Gunson B, Hathaway M, Brown R, Nightingale P, Cockwell P, Hubscher SG, Adams DH, Moss P, Briggs D. Donor HLA-C genotype has a profound impact on the clinical outcome following liver transplantation. Am J Transplant 2008; 8: 1931-1941
156. Moya-Quiles MR, Alvarez R, Miras M, Gomez-Mateo J, Lopez-Alvarez MR, Marin-Moreno I, Martínez-Barba E, Sanchez-Mozo MP, Gomez M, Arnal F, Sanchez-Bueno F, Marin LA, Garcia-Alonso AM, Minguela A, Muro M, Par-rilla P, Alonso C, Alvarez-López MR. Impact of recipient HLA-C in liver transplant: a protective effect of HLA-Cw*07 on acute rejection. Hum Immunol 2007; 68: 51-58
157. Moreso F, Ibernon M, Gomà M, Carrera M, Fulladosa X, Hueso M, Gil-Vernet S, Cruzado JM, Torras J, Grinyó JM, Serón D. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006; 6: 747-752
158. Emiroǧlu R, Yagmurdur MC, Karakayali F, Haberal C, Ozcelik U, Colak T, Haberal M. Role of donor age and acute rejection episodes on long-term graft survival in cadaveric kidney transplantations. Transplant Proc 2005; 37: 2954-2956
159. Meier-Kriesche HU, Ojo AO, Hanson JA, Cibrik DM, Punch JD, Leichtman AB, Kaplan B. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation 2000; 70: 1098-1100
160. Hübscher S. Diagnosis and grading of liver allograft rejection: a European perspective. Transplant Proc 1996; 28: 504-507
161. Calne RY, Sells RA, Pena JR, Davis DR, Millard PR, Herb-ertson BM, Binns RM, Davies DA. Induction of immunolog-ical tolerance by porcine liver allografts. Nature 1969; 223: 472-476
162. Kamada N. The immunology of experimental liver transplantation in the rat. Immunology 1985; 55: 369-389
163. Qian S, Demetris AJ, Murase N, Rao AS, Fung JJ, Starzl TE. Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology 1994; 19: 916-924
164. Mor E, Gonwa TA, Husberg BS, Goldstein RM, Klintmalm GB. Late-onset acute rejection in orthotopic liver transplan-tation--associated risk factors and outcome. Transplantation 1992; 54: 821-824
165. Cakaloglu Y, Devlin J, O'Grady J, Sutherland S, Portmann BC, Heaton N, Tan KC, Williams R. Importance of concomitant viral infection during late acute liver allograft rejection. Transplantation 1995; 59: 40-45
166. Anand AC, Hubscher SG, Gunson BK, McMaster P, Neu-berger JM. Timing, signifcance, and prognosis of late acute liver allograft rejection. Transplantation 1995; 60: 1098-1103
167. Ramji A, Yoshida EM, Bain VG, Kneteman NM, Scudamore CH, Ma MM, Steinbrecher UP, Gutfreund KS, Erb SR, Parto-vi N, Chung SW, Shapiro J, Wong WW. Late acute rejection after liver transplantation: the Western Canada experience. Liver Transpl 2002; 8: 945-951
168. Florman S, Schiano T, Kim L, Maman D, Levay A, Gon-dolesi G, Fishbein T, Emre S, Schwartz M, Miller C, Sheiner P. The incidence and signifcance of late acute cellular rejection (> 1000 days) after liver transplantation. Clin Transplant 2004; 18: 152-155
169. Kubota T, Thomson A, Clouston AD, Nakazawa Y, Stead-man C, Kerlin P, Shimada H, Balderson GA, Lynch SV, Strong RW. Clinicopathologic fndings of recurrent primary sclerosing cholangitis after orthotopic liver transplantation. J Hepatobiliary Pancreat Surg 1999; 6: 377-381
170. Lidén H, Norrby J, Gäbel M, Friman S, Olausson M. Outcome after liver transplantation for primary sclerosing chol-angitis. Transplant Proc 2001; 33: 2452-2453
171. Renz JF, Ascher NL. Liver transplantation for nonviral, nonmalignant diseases: problem of recurrence. World J Surg 2002; 26: 247-256
172. Yusoff IF, House AK, De Boer WB, Ferguson J, Garas G, Heath D, Mitchell A, Jeffrey G. Disease recurrence after liver transplantation in Western Australia. J Gastroenterol Hepatol 2002; 17: 203-207
173. Khuroo MS, Al Ashgar H, Khuroo NS, Khan MQ, Khalaf HA, Al-Sebayel M, El Din Hassan MG. Biliary disease after liver transplantation: the experience of the King Faisal Specialist Hospital and Research Center, Riyadh. J Gastroenterol Hepatol 2005; 20: 217-228
174. Ołdakowska-Jedynak U, Nowak M, Mucha K, Foroncewicz B, Nyckowski P, Zieniewicz K, Ziarkiewicz-Wróblewska B, Patkowski W, Górnicka B, Paczkowska A, Michałowicz B, Pilecki T, Pawlak J, Krawczyk M, Paczek L. Recurrence of primary sclerosing cholangitis in patients after liver transplantation. Transplant Proc 2006; 38: 240-243
175. Yamagiwa S, Ichida T. Recurrence of primary biliary cirrhosis and primary sclerosing cholangitis after liver transplantation in Japan. Hepatol Res 2007; 37 Suppl 3: S449-S454
176. Tamura S, Sugawara Y, Kaneko J, Matsui Y, Togashi J, Makuuchi M. Recurrence of primary sclerosing cholangitis after living donor liver transplantation. Liver Int 2007; 27: 86-94
177. Kashyap R, Mantry P, Sharma R, Maloo MK, Safadjou S, Qi Y, Jain A, Maliakkal B, Ryan C, Orloff M. Comparative analysis of outcomes in living and deceased donor liver transplants for primary sclerosing cholangitis. J Gastrointest Surg 2009; 13: 1480-1486
178. Moncrief KJ, Savu A, Ma MM, Bain VG, Wong WW, Tan-don P. The natural history of infammatory bowel disease and primary sclerosing cholangitis after liver transplanta-tion--a single-centre experience. Can J Gastroenterol 2010; 24: 40-46
179. Klintmalm GB, Nery JR, Husberg BS, Gonwa TA, Tillery GW. Rejection in liver transplantation. Hepatology 1989; 10: 978-985
180. McEntee G, Wiesner RH, Rosen C, Cooper J, Wahlstrom E. A comparative study of patients undergoing liver transplantation for primary sclerosing cholangitis and primary biliary cirrhosis. Transplant Proc 1991; 23: 1563-1564
181. Shaked A, Colonna JO, Goldstein L, Busuttil RW. The interrelation between sclerosing cholangitis and ulcerative colitis in patients undergoing liver transplantation. Ann Surg 1992; 215: 598-603; discussion 604-605
182. Bathgate AJ, Pravica V, Perrey C, Therapondos G, Plevris JN, Hayes PC, Hutchinson IV. The effect of polymorphisms in tumor necrosis factor-alpha, interleukin-10, and transforming growth factor-beta1 genes in acute hepatic allograft rejection. Transplantation 2000; 69: 1514-1517